All In Biotech

Drug Trial Radar · NCT01426269

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® Capsules Compared to Placebo After an Initial 12 Week Treatment Regimen With Oracea® and MetroGel® 1% in Adults With Rosacea

Last checked: Nov 20, 2026Latest source record: Aug 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 235 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

235

Actual

Start

Sep 2011

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Aug 31, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.

Conditions

  • Rosacea

Interventions

  • DoxycyclineDrug

    During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning

  • MetronidazoleDrug

    During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area

  • PlaceboDrug

    During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Period 2: Number of Subjects Who RelapsedTime frame: Period 2 (40 weeks)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • ATS Clinical Research

    Santa Monica, California

  • Dadeland Dermatology

    Coral Gables, Florida

  • Melissa L. F. Knuckles M.D., P.S.C.

    Corbin, Kentucky

  • Dermatology Specialists Research

    Louisville, Kentucky

  • Melissa L. F. Knuckles M.D., P.S.C.

    Richmond, Kentucky

  • The Maryland Laser, Skin, and Vein Institute, LLC

    Hunt Valley, Maryland

  • Grekin Skin Institute

    Warren, Michigan

  • Hilary Baldwin

    Brooklyn, New York

  • The Center for Dermatology at Linden Oaks

    Rochester, New York

  • Brodell Medical, Inc.

    Warren, Ohio

  • Center for Dermatology and Laser Surgery

    Portland, Oregon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.